OPKO Health to Participate at Upcoming Healthcare Investment Conferences
February 21 2017 - 5:18PM
OPKO Health, Inc. (NASDAQ:OPK) today announced
that senior management will participate at the 2017 RBC Capital
Markets’ Healthcare Conference taking place February 22-23, 2017 at
the New York Palace Hotel and at the Cowen Group’s 37th Annual
Health Care Conference taking place March 6-8, 2017 at The Boston
Marriott Copley Place.
2017 RBC Capital Markets’ Healthcare Conference
Date and Time: Thursday, February 23, 2017,
11:00 AM ETFormat: Company presentation
Presenter: OPKO Health Senior Management
Cowen Group’s 37th Annual Health Care
Conference
Date: March 6, 2017
Format: One-on-One
MeetingsPresenter: OPKO Health Senior
Management
The 2017 RBC Capital Markets’ Healthcare Conference presentation
will be webcast live on the OPKO Investor Relations page of the
corporate website at www.opko.com. To access the live webcast
please log onto the OPKO website approximately fifteen minutes
before the presentation to register and download any necessary
audio software. The audio presentation will be available at
this link for a limited time after the live presentation.
About OPKO Health, Inc.OPKO Health is a
diversified healthcare company that seeks to establish
industry-leading positions in large, rapidly growing markets. Our
diagnostics business includes Bio-Reference Laboratories, the
nation's third-largest clinical laboratory with a core genetic
testing business and a 400-person sales and marketing team to drive
growth and leverage new products, including the 4Kscore® prostate
cancer test and the Claros® 1 in-office immunoassay platform. Our
pharmaceutical business features RAYALDEE, an FDA-approved
treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency (launched in November 2016), VARUBI™ for
chemotherapy-induced nausea and vomiting (oral formulation launched
by partner TESARO and IV formulation pending FDA approval), TT401,
a once or twice weekly oxyntomodulin for type 2 diabetes and
obesity which is a clinically advanced drug candidate among the new
class of GLP-1 glucagon receptor dual agonists, and TT701, an
androgen receptor modulator for androgen deficiency
indications. Our biologics business includes hGH-CTP, a
once-weekly human growth hormone injection (in phase 3 and
partnered with Pfizer), a long-acting Factor VIIa drug for
hemophilia (in phase 2a) and a long-acting oxyntomodulin for
diabetes and obesity (in phase 1). We also have production and
distribution assets worldwide, multiple strategic investments and
an active business development strategy. More information is
available at www.opko.com.
Contacts:
OPKO Health, Inc.
David Malina, 305-575-4100
Investor Relations
or
Media
Rooney & Associates
Terry Rooney, 212-223-0689
trooney@rooneyco.com
or
Marion Janic, 212-223-4017
mjanic@rooneyco.com
or
Investors
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024